SPRY2 attenuates B-cell receptor (BCR) and MAPK-ERK signaling by binding to CRAF and BRAF in normal B cells and chronic lymphocytic leukemia (CLL) cells [216]. This evidence concerns the gene BRAF and B-cell chronic lymphocytic leukemia.